Brain Pharm - Pathological mechanism

	Name
1	Abeta inhibits late LTP in animal models of Alzheimers
2	Abeta inhibits LTP both in soluble and fibrillar conformational states
3	Abeta inhibits LTP through TNFalpha
4	Abeta oligomer inhibits p-21 activated kinase and stimulates ROCK signalling
5	Abeta peptides block LTP in rat CA1 in vivo
6	Aging decreases NMDA receptors and increases GABA A-receptor mediated inhibition
7	AMPA receptor downscaling in AD
8	Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP
9	beta-Amyloid impairs LTP/LTD
10	beta-Amyloid-induced depression of LTP attenuated by Verapamil
11	Inhibition of I_L impairs LTP in CA1 in vivo
12	LTP requires BDNF and is associated with cytoskeleton-associated protein
13	Memantine reduces APP, Galantamine and Nicotine increase synaptophysin
14	Nicotine desensitize alpha7 nACh receptors and facilitates LTP
15	Serum magnesium level correlates with clinical deterioration in Alzheimer's